Barrington analyst Michael Petusky maintained a Buy rating on Lemaitre Vascular (LMAT) today and set a price target of $37. The company’s shares closed yesterday at $33.40.
Petusky commented:
“We continue to think that recent geographic expansion and new product innovations (like the just-launched XenoSure Plus) will give LMAT a reasonable opportunity to sustain its recent pickup in organic momentum over the longer term.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 5.0% and a 54.7% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
Currently, the analyst consensus on Lemaitre Vascular is a Moderate Buy with an average price target of $32.
See today’s analyst top recommended stocks >>
Lemaitre Vascular’s market cap is currently $657M and has a P/E ratio of 29.96. The company has a Price to Book ratio of 4.94.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LMAT in relation to earlier this year. Earlier this month, John James O’connor, a Director at LMAT bought 7,500 shares for a total of $59,025.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease.
